Clinical Approaches in High-Risk Patients with CLL/SLL
Mazyar Shadman, MD, MPH, describes his clinical approach to treating patients with high-risk CLL/SLL, including those with or without del(17p) or TP53 mutations.
Video content above is prompted by the following questions:
- How would you describe your current clinical approach for high-risk patients with CLL/SLL, including those with or without del(17p) and/or TP53 mutations?
- What are the goals of therapy for patients in this setting?
- What are some challenges and unmet needs for patients with CLL/SLL?
Recent Videos
Related Content
Resistance Mutations Develop Differently After Noncovalent BTK Therapy in CLL
May 14th 2025Article
During a live event, Shuo Ma, MD, PhD, discussed the resistance mutation analysis of patients who had disease progression after receiving pirtobrutinib for BTK inhibitor–pretreated chronic lymphocytic leukemia.
Read More
